Evidence map›Paper›PMID 37946031›Full record

ArticleAnnals of hematology2024

Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Kotaro Shide, Katsuto Takenaka, Akira Kitanaka, Akihiko Numata, Takuro Kameda, Takuji Yamauchi, Atsushi Inagaki, Shohei Mizuno, Akiyoshi Takami, Shinichi Ito and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 16 institutions in 1 country.

Kotaro ShideDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan.
Katsuto TakenakaDepartment of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Akira KitanakaDepartment of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.
Akihiko NumataDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Takuro KamedaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan.
Takuji YamauchiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Atsushi InagakiDepartment of Hematology and Oncology, Nagoya City West Medical Center, Nagoya, Japan.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Akiyoshi TakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Shinichi ItoDepartment of Hematology, Hakodate City Hospital, Hakodate, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Takaaki MaekawaDivision of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Okayama, Japan.
Miyuki TsutsuiDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Keiya OzawaDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shunya AraiDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Mibu, Tochigi, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan. kshimoda@med.miyazaki-u.ac.jp.
Juntendo University · JPKyushu University · JPUniversity of Miyazaki · JPAichi Medical University · JPThe University of Tokyo · JPDokkyo Medical University · JPEhime University · JPEiju General Hospital · JPHakodate National Hospital · JPJichi Medical University · JPKawasaki Medical School · JPKurashiki Central Hospital · JPNagoya Medical Center · JPNational Defense Medical College · JPNTT Medical Center · JPOkayama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are few prospective studies on patients with post-essential thrombocythemia myelofibrosis (PET-MF) and post-polycythemia vera myelofibrosis (PPV-MF). Therefore, we conducted a nationwide longitudinal prospective survey to clarify the clinical characteristics of these diseases. A total of 197 PET-MF and 117 PPV-MF patients diagnosed between 2012 and 2021 were analyzed. The median age at diagnosis was 70.0 years for both diseases. The time from diagnosis of ET or PV to that of MF was 9.6 and 10.4 years, respectively, with no significant difference. Patients with PPV-MF had higher hemoglobin levels and white blood cell counts than those with PET-MF, whereas those with PET-MF had higher platelet counts than those with PPV-MF. Although splenomegaly was more frequent in patients with PPV-MF at diagnosis, there was no difference in the frequency of constitutional symptoms. Ruxolitinib was the most common treatment administered to 74.6% and 83.8% of patients with PET-MF and PPV-MF, respectively. Patients with PET-MF and PPV-MF had similar prognoses, with 3-year overall survival (OS) of 0.742 in PET-MF and 0.768 in PPV-MF patients. In both diseases, leukemic transformation was the leading cause of death, followed by infection. The 3-year OS for patients with PET/PPV-MF and primary MF diagnosed during the same period was 0.754 and 0.626, respectively, with no significant difference. This survey provides real-world clinical features and prognostic data on secondary myelofibrosis in the ruxolitinib era.

Indexed as

Polycythemia VeraPrimary MyelofibrosisThrombocythemia, EssentialAgedHumansNitrilesProspective StudiesPyrazolesPyrimidinesNitrilesPyrazolesPyrimidinesruxolitinibPost-essential thrombocythemia myelofibrosisPost-polycythemia vera myelofibrosisPrimary myelofibrosisRuxolitinib

Identifiers

PMID37946031
OpenAlexW4388552268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.